Here, we report the safety and efficacy of pamiparib in a phase II, multicenter study in Chinese patients with locally advanced or metastatic HER2− breast cancer harboring germline BRCA1/2 mutations (gBRCA1/2 m). The gene discussed is BRCA1; the disease is breast cancer.